UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations

/in , , , /by

New phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]

Read more

UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001

/in , , , /by

Updated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]

Read more

UPDATE: JNJ-6143 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

Updated phase 1 results provide further evidence of activity for JNJ-6143, previously known as HLD-0915 and also referred to as JNJ-101556143, in heavily pretreated metastatic castration-resistant prostate cancer. Following our previous coverage of its initial results and a separate phase 2 trial, the new findings add dose-specific outcomes and exploratory molecular data. JNJ-6143 is an […]

Read more

Phase 1 ProTACT: Actinium-225 FL-020 Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results show preliminary antitumor activity for 225Ac-FL-020, an investigational PSMA-targeted alpha radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from ProTACT, an ongoing first-in-human phase 1 trial evaluating the safety, dosing, and preliminary efficacy of FL-020 in patients previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, unless chemotherapy […]

Read more

UPDATE: EIK1003 Plus Abiraterone Shows Early Activity in HRR-Mutated Prostate Cancer

/in , , , /by

New results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]

Read more

UPDATE: Gedatolisib Plus Darolutamide Shows Activity in mCRPC

/in , , , /by

Updated results from the phase 1/2 CELC-G-201 trial (we talked about it in this previous article) provide new evidence of antitumor activity for gedatolisib combined with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs). Gedatolisib inhibits the PI3K–AKT–mTOR signaling pathway, which can contribute to resistance to […]

Read more

Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer

/in , , /by

Updated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]

Read more

Phase 1 Trial: Astatine-211 PSMA-5 Shows Strong Early Responses in First-in-Human Prostate Cancer Trial

/in , , /by

Encouraging results suggest that 211At-PSMA-5, an experimental alpha-emitting radioligand targeting PSMA, may offer a promising new treatment approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human phase 1 study involving 15 patients whose disease had progressed following androgen receptor pathway inhibitors and taxane-based chemotherapy. Unlike established PSMA-targeted radioligand therapy […]

Read more

Phase 1 Trial for SHR-4394: PSMA-Targeted ADC Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results provide encouraging preliminary evidence of antitumor activity for SHR-4394, an investigational antibody-drug conjugate (ADC) targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human 1hase 1 study evaluating SHR-4394 as a standalone treatment. The drug is designed to recognize PSMA, a protein frequently expressed on prostate cancer cells, and […]

Read more

UPDATE: ABBV-969 Shows Strong Molecular Responses in Advanced Prostate Cancer

/in , , /by

New biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]

Read more